Revolution Medicines Inc
For the period ended Dec 31, 2023. Filed Feb 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 26, 2024
RVMD$200.15+4.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | December 31, | |
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $696,148 | $161,412 |
| Marketable securities | 1,156,807 | 483,531 |
| Accounts receivable | 1,254 | 4,673 |
| Prepaid expenses and other current assets | 25,072 | 10,569 |
| Total current assets | 1,879,281 | 660,185 |
| Property and equipment, net | 22,865 | 18,659 |
| Operating lease right-of-use asset | 77,149 | 55,077 |
| Intangible assets, net | 57,739 | 58,807 |
| Goodwill | 14,608 | 14,608 |
| Restricted cash | 3,031 | 1,737 |
| Other noncurrent assets | 7,032 | 2,857 |
| Total assets | $2,061,705 | $811,930 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $61,788 | $21,306 |
| Accrued expenses and other current liabilities | 74,694 | 29,446 |
| Operating lease liability, current | 7,369 | 6,773 |
| Deferred revenue, current | — | 4,459 |
| Total current liabilities | 143,851 | 61,984 |
| Deferred tax liability | 3,115 | 7,025 |
| Operating lease liability, noncurrent | 80,575 | 57,432 |
| Warrant liability | 6,512 | — |
| Other noncurrent liabilities | 1,458 | 301 |
| Total liabilities | 235,511 | 126,742 |
| Commitments and contingencies (Note 8) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; none issued and outstanding at December 31, 2023 and December 31, 2022, respectively | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 170,234,594 and 90,411,912 shares issued as of December 31, 2023 and December 31, 2022; 164,674,594 and 90,411,912 shares outstanding as of December 31, 2023 and December 31, 2022, respectively | 16 | 9 |
| Additional paid-in capital | 2,963,342 | 1,388,300 |
| Accumulated other comprehensive income (loss) | 544 | (1,780) |
| Accumulated deficit | (1,137,708) | (701,341) |
| Total stockholders' equity | 1,826,194 | 685,188 |
| Total liabilities and stockholders' equity | $2,061,705 | $811,930 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.